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Abstract A review of the literature finds that women
diagnosed with breast cancer, who were on an aspirin
regimen, experienced a decreased risk of distant metastases
and death. Several recent studies have reported an
improvement in overall survival in colorectal cancer
patients who harbored mutations in the oncogene PIK3CA
and received a daily aspirin regimen. Breast cancer patients
on a daily aspirin regimen experienced decreased risk of
distant metastases and death. PIK3CA is the most fre-
quently mutated oncogene in breast cancer, occurring in up
to 45 % of all breast cancers. In order to determine if
mutations in PIK3CA sensitized breast cancers to aspirin
treatment, we employed the use of isogenic cellular clones
of the non-tumorigenic, breast epithelial cell line MCF-
10A that harbored mutations in either PIK3CA or KRAS or
both. We report that mutations in both PIK3CA and KRAS
are required for the greatest aspirin sensitivity in breast
cancer, and that the GSK3b protein was hyperphosphory-
lated in aspirin-treated double knockin cells, but not in
other clones/treatments. A more modest effect was
observed with single mutant PIK3CA, but not KRAS alone.
These observations were further confirmed in a panel of
breast cancer cell lines. Our findings provide the first evi-
dence that mutations in PIK3CA sensitize breast cancer
cells to aspirin.
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Abbreviations
CD-FBS Charcoal-dextran treated fetal bovine serum
DKI Cellular clones of MCF-10A carrying
mutations in PIK3CA in combination with
KRAS
DMEM:F12 Dulbecco’s modified eagle medium
EGF Epidermal growth factor
FACS Fluorescence-activated cell sorting
FBS Fetal bovine serum
MPE Molecular pathologic epidemiology
NSAID Non-steroidal anti-inflammatory drug
PI3K Phosphatidylinositol-4,5-bisphosphate
3-kinase
RPPA Reverse phase protein array
TRIS Tris(hydroxymethyl)aminomethane
Introduction
In 2015, over 227,000 women will be newly diagnosed
with breast cancer in the United States, while nearly 40,000
women who already have breast cancer will succumb to the
disease [1]. The majority of women with breast cancer who
succumb to their disease exhibit resistance to all available
therapies. Moreover, the number of available targeted
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therapies is limited by (i) the number of disease-relevant
genetic alterations that have been identified and (ii) the
number of therapeutic agents available for known targets.
The past decade has seen a steady surge in the use of
targeted therapies in cancer. Aspirin is a common non-
steroidal anti-inflammatory drug (NSAID) often used for
the prevention of heart disease [2]. Several NSAIDs have
been shown to inhibit cell growth and lead to apoptosis
during different stages of cancer [3, 4]. Regular aspirin use
has been reported to prevent several types of cancers and
more recently has been shown to have anti-cancer prop-
erties [2, 5–7]. Aspirin inhibits PTGS2 (cyclooxygenase),
which therefore prevents the conversion of arachidonic
acid into prostaglandins. Clinically, aspirin acts as an anti-
inflammatory and antiplatelet agent. Others have specu-
lated that regular aspirin use can prevent the development
of cancers [8, 9].
A review of the literature reveals that most cancer-re-
lated aspirin studies have been in the context of cancer
prevention [3, 6, 7, 9]. Holmes et al. [10] reported that
women diagnosed with breast cancer and taking a regular
aspirin regimen experienced a decreased risk of distant
recurrence of the disease and breast cancer death [10].
Similar observations have been made in other cancers [11–
13]. Of note, patients diagnosed with colorectal cancers
harboring mutations in PIK3CA and receiving aspirin
treatment had increased survival [11–13].
The PIK3CA gene encodes the catalytic domain of the
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)
complex. Dysregulation of the PI3K complex leads to
unabated growth signaling through the AKT and MAPK
pathways and is strongly implicated in the pathogenesis of
many cancers [14]. The PIK3CA gene is frequently muta-
ted in both colorectal and breast cancers, occurring in up to
32 and 45 %, respectively [15, 16].
Taken together, we hypothesized that physiologic con-
centrations of aspirin may have an anti-proliferative effect
on breast cancers harboring mutations in PIK3CA. To test
this hypothesis, we utilized an isogenic cellular model of
mutant PIK3CA in the human, non-tumorigenic breast
epithelial cell line, MCF-10A [17, 18]. To the best of our
knowledge, this is the first study to explore the mechanism
of the anti-cancer properties of aspirin in the context of
breast cancers harboring mutations in PIK3CA.
Methods
Cell culture
The non-tumorigenic human breast epithelial cell line
MCF-10A (ATCC, Manassas, VA) and its derivatives were
grown in a humidified atmosphere, supplemented with
5.1 % CO2 at 37 C in Dulbecco’s modified eagle medium
(DMEM:F12) devoid of phenol-red (Life Technologies,
Grand Island, NY) supplemented with 5 % horse serum
(Sigma, Saint Louis, MO), 1 % penicillin and streptomycin
(Life Technologies, Grand Island, NY), 20 ng/mL epider-
mal growth factor (EGF) (Sigma, Saint Louis, MO), 25 lg/mL
insulin (Sigma, Saint Louis, MO), 0.5 lg/mL hydrocorti-
sone (Sigma, Saint Louis, MO), and 0.1 lg/mL cholera
toxin (Sigma, Saint Louis, MO) (hereafter referred to as
‘‘supplemented medium’’) as previously described [18].
MCF-7, MDA-MB-468, and MDA-MB-436 cells (ATCC,
Manassas, VA) were grown in DMEM (Life Technologies)
supplemented with 5 % fetal bovine serum (FBS) (Sigma,
Saint Louis, MO) and 1 % penicillin streptomycin (Life
Technologies, Grand Island, NY). Cellular clones of MCF-
10A carrying mutations in PIK3CA alone or in combina-
tion with KRAS (hereafter referred to as ‘‘DKI’’) were a
generous gift from Dr. Ben Ho Park (Johns Hopkins
University) and were grown in EGF-free supplemented
medium (hereafter referred to as ‘‘knockin medium’’) [18].
All cellular assays of MCF-10A cells and its derivatives
were performed in knockin medium, whereby horse serum
was replaced with 1 % charcoal-dextran treated fetal
bovine serum (CD-FBS) (Fisher Scientific, Pittsburg, PA)
(hereafter referred to as ‘‘assay medium’’). The cancer cell
lines MCF-7, MDA-MB-468, and MDA-MB-436 were
seeded in ‘‘cancer assay medium’’ which consisted of
DMEM supplemented with 1 % penicillin and strepto-
mycin, and 0.5 % CD-FBS. All cells were harvested for
passaging using Tryple Express (Life Technologies, Grand
Island, NY).
Cellular proliferation assays
Cells were plated in 96-well plates at a density of 2000
cells/well in assay medium. After 24 h (day 1), the medium
was replaced with fresh assay medium supplemented with
0.2 ng/mL EGF and 0, 2, 3, or 4 mM aspirin (Sigma, Saint
Louis, MO) and replenished on day 2. On day 4, cells were
stained with either crystal violet or CellTiter-Fluor cell
viability assay (Promega, Madison, WI) and counted by
measuring absorbance on a SpectraMax M5 fluorescence
plate reader (Molecular Devices, Sunnydale, CA), as pre-
viously described [19].
Immunoblotting
Cells were seeded and treated as above, except fresh
aspirin-containing medium was added 1 h before harvest-
ing, as previously described [20]. Whole cell lysates were
harvested on days 1 and 4 with and without aspirin in
Laemmli Buffer (Bio Rad, Hercules, CA) and boiled for
10 min at 100 C. Lysates were resolved using SDS-PAGE
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using 4–12 % bis–tris NuPAGE gels in MES running
buffer (Invitrogen, Grand Island, NY) following the man-
ufacturer’s protocol. The proteins were transferred using
Invitrogen Xcell II blotting apparatus to a PVDF mem-
brane (Invitrogen, Grand Island, NY). Following transfer,
the membranes were blocked in 5 % w/v milk in tris(hy-
droxymethyl)aminomethane (TRIS)-buffered saline sup-
plemented with 0.1 % tween-20 (Sigma, Saint Louis, MO)
for 1 h. Membranes were probed with either phosphory-
lated GSK3b (Ser 9; 9336), total GSK3b (9315), phos-
phorylated Src family (Tyr 416; 2101), total Src (ab47405,
Abcam, Cambridge, MA), ACTB (b-actin) (4967), and
TUBB (b-tubulin) (2146) primary antibody followed by
incubation with an anti-rabbit secondary antibody conju-
gated to horseradish peroxidase (7074). Protein bands were
visualized using enhanced chemiluminescent reagent
(Perkin-Elmer, Waltham, MA). All antibodies were pur-
chased from Cell Signaling Technology (Beverly, MA)
unless otherwise noted. Densitometry was performed using
Image J analysis software (NIH).
Fluorescence-activated cell sorting (FACS)
Parental MCF-10A cells and DKI cells were plated under
assay conditions and treated with either 0, 2, 3, or 4 mM
aspirin for up to 72 h. Cells were seeded at 50,000 cells/
well on assay medium in 24-well plates. After 24 h, assay
media were removed, and cells were replenished with assay
medium supplemented with 0.2 ng/mL EGF and 0–4 mM
of aspirin. Camptothecin (2–100 lg/mL) (Sigma, Saint
Louis, MO) served as a positive control for cell death.
After 72 h, the media were removed, and cells were
washed with Hank’s Balanced Salt solution (Corning,
Corning, NY). Cells were harvested, and the pellets were
resuspended in phosphate buffered saline and FACS buffer.
Propidium iodine (Sigma, Saint Louis, MO) was added to
each sample at 7 lg/mL for 5 min prior to analysis. Har-
vested samples and single stain controls were run on
FACSCanto (Becton–Dickinson, Franklin Lakes, NJ) and
analyzed for cell cytotoxicity.
Reverse phase protein array (RPPA)
Parental MCF-10 and DKI cells were seeded on day 0 in
EGF-free assay medium. The medium was replaced with
assay medium supplemented or not with 4 mM aspirin the
following day and cells were grown for the additional
3 days. Following harvesting, cell pellets were sent to the
RPPA core facility at The MD Anderson Cancer Center for
further preparation and analysis.
Cellular proteins were denatured by 1 % SDS (with b-
mercaptoethanol) and diluted in five 2-fold serial dilutions
in dilution buffer (lysis buffer containing 1 % SDS). Serial
diluted lysates were arrayed on nitrocellulose-coated slides
(Grace Biolab) by Aushon 2470 Arrayer (Aushon
BioSystems). A total of 5808 array spots were arranged on
each slide including the spots corresponding to positive and
negative controls prepared from mixed cell lysates or
dilution buffer, respectively. Each slide was probed with a
validated primary antibody plus a biotin-conjugated sec-
ondary antibody.
Statistical analyses
Statistical analysis was performed using a student’s t test.
A P value of less than 0.05 was considered significant.
For analysis of our RRPA results, only antibodies with a
Pearson correlation coefficient between RPPA and Western
blotting of greater than 0.7 were used in reverse phase
protein array study. The signal obtained was amplified
using a Dako Cytomation—catalyzed system (Dako) and
visualized by DAB colorimetric reaction. The slides were
scanned, analyzed, and quantified using a customized-
software Microvigene (VigeneTech Inc.) to generate spot
intensity.
Each dilution curve was fitted with a logistic model
(‘‘Supercurve Fitting’’ developed by the Department of
Bioinformatics and Computational Biology in MD
Anderson Cancer Center, http://bioinformatics.mdander
son.org/OOMPA). The similarity in samples to each other
was determined by Pearson correlation. The correlation
values for each of the expression nodes were calculated by
the RPPA core where it was determined that correlation of
0.195, coupled with more than 100 of freedom (i.e.,
antibodies), has a P value of 0.05.
Results
Mutations in oncogenes sensitize breast cancer cells
to aspirin
In order to isolate the effects of physiologic levels of
aspirin in the presence of specific mutations, we employed
an isogenic cellular system derived from the human non-
tumorigenic cell line, MCF-10A, which is devoid of any
other oncogenic mutations. However, it should be noted
that these cells carry a deletion in the p16/ARF locus,
which is thought to contribute to their immortalization
[21]. This cell line is dependent on EGF for growth, thus
removing EGF from the medium results in G1 arrest.
Clones carrying mutant PIK3CA are EGF independent but
still respond to EGF. Therefore, cells are initially plated in
the absence of EGF to synchronize cells, and then 0.2 ng/mL
of EGF is added to drug containing medium 24 h later.
We chose a lower dose of EGF than what is in the typical
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growth medium because our previous studies have shown
that high doses of EGF mask the contribution of mutant
PIK3CA to cellular signaling [17].We tested varying doses
of aspirin for 24, 48, and 72 h and determined that the most
prominent effect of aspirin was observed after 72 h.
Therefore, all aspirin experiments were performed for 72 h
post aspirin treatment. The half maximal inhibitory con-
centration (IC50) value for each cellular clone was calcu-
lated and reported in Supplementary Table 1. Parental
MCF-10A cells were not responsive up to 4 mM aspirin
(Fig. 1). However, aspirin treatment of cells carrying
mutations in PIK3CA at either exon 9 (E545K) or exon 20
(H1047R), resulted in a statistically significant decrease in
cell number (Fig. 1). We and others have shown that
individual genetic lesions may not be sufficient for
tumorigenesis, but the accumulation of genetic lesions over
time results in a phenotype more consistent with trans-
formed cells [15, 18, 22]. Therefore, we tested the effects
of aspirin on clones of the MCF-10A cell line that con-
currently carried activating mutations in both KRAS
(G12V) and PIK3CA (either exon 9 or exon 20) [18]. As
expected, the combination of activated oncogenes resulted
in a statistically significant decrease in cellular prolifera-
tion of up to a 40 % (Fig. 1). Interestingly, cells were not
responsive to aspirin in the presence of mutant KRAS
alone, albeit a small non-significant decrease was observed,
thus indicating that mutant PIK3CA is required for aspirin
sensitivity (Fig. 1) and concomitant activating mutations in
other genes enhance this effect. In the current study,
mutations in both PIK3CA and KRAS are likely cooper-
ating to promote more stable activation of the GSK3b
pathway. This effect is likely mediated by the RAS binding
domain on PIK3CA, as we have previously demonstrated
that inactivating mutations in this domain decreased the
cooperative effects of the mutant PIK3CA and mutant
KRAS [23].
Aspirin is a known inhibitor of PTGS1 and PTGS2,
enzymes responsible for formation of prostanoids. In order
to determine if inhibition of these enzymes resulted in the
growth inhibitory effects that we observed, MCF-10A and
DKI (Exon 9/KRAS) cells were treated with the PTGS2
inhibitor celecoxib, at a physiological dose of 10 lM and
toxic dose of 25 lM [24]. Neither cellular clone was
growth inhibited by 10 lM celecoxib, but both clones were
equally growth inhibited at 25 lM (Fig. 2), suggesting that
observed differences in cell number following aspirin
treatment were not a result of PTGS2 inhibition.
Next, we used FACS to determine if the decrease in
cellular proliferation was cytostatic or cytocidal. As seen in
Fig. 3, parental MCF-10A cells were unaffected by aspirin
treatment. However, a dose-dependent, statistically signif-
icant increase in cytotoxicity was observed in DKI cells
(relative to aspirin-free control cells), as indicated by the
increase in propidium iodide staining.
Fig. 1 Effect of aspirin on
parental (MCF-10A), individual
knockin mutations of either
PIK3CAH1047R, PIK3CAE545K,
KRASG12V, and double mutant
knock-ins of KRASG12Vwith
either PIK3CAH1047R or
PIK3CAE545K clones of MCF-
10A were treated with varying
doses of aspirin for 72 h.
Parental and clones of MCF-
10A were seeded on day 0 in
EGF-free media. Following
24 h, the media were replaced
with assay media containing
0.2 ng/mL EGF and
supplemented with 0–4 mM
aspirin. Cells were counted after
72 h. Values for cells treated
with 2, 3, and 4 mM aspirin
were normalized to the
respective 0 mM aspirin value
for that particular cell line.
Values represent mean ± SEM
(*P\ 0.05, n = 4)
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Aspirin alters cellular signaling in mutant PIK3CA-
containing cells
Next, we attempted to define a mechanism of aspirin’s
action in mutant PIK3CA-containing cells. Therefore, we
turned to a reverse phase protein array (RPPA) to identify
proteins that are differentially expressed following aspirin
treatment and may account for the cytotoxicity observed in
DKI cells. The values of aspirin-treated cells provided by
RPPA analysis for each cell line were normalized to the
Fig. 2 Effect of celecoxib on
parental (MCF-10A; white) and
double mutant knock-ins of
KRASG12V with PIK3CAE545K
(black) clones of MCF-10A
were treated with various
concentrations of celecoxib for
72 h. Parental MCF-10A and
clone of MCF-10A were seeded
on day 0 in EGF-free media.
Following 24 h, the media were
replaced with assay media
containing 0.2 ng/mL EGF and
supplemented with 0, 10 or
25 lM celecoxib. Cells were
counted after 72 h. Cell values
for 10 or 25 lM celecoxib were
normalized to the respective
0 mM celecoxib value for that
particular cell line. Values
represent mean ± SD
(*P\ 0.05, n = 3)
Fig. 3 Cytotoxic effect of
aspirin on parental MCF-10A
and MCF-10A DKI (Exon
9/KRAS) cells. Parental (circle)
and DKI (square) were seeded
on day 0 in EGF-free media for
24 h. The media were then
replaced with assay media
containing 0.2 ng/mL EGF and
supplemented with 0–4 mM
aspirin. Cytotoxicity was
evaluated after 72 h by
measuring uptake of propidium
iodide by FACS analysis.
Values represent mean ± SD
(*P\ 0.05, n = 3)
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respective untreated cells. Proteins were ranked based upon
the normalized value. The top two proteins were phos-
phorylated GSK3b (Ser9) and Src (Tyr 416) in aspirin-
treated DKI cells, relative to aspirin-free control DKI cells.
However, these protein marks were not differentially
expressed in parental MCF-10A cells (Supplementary
Fig. 1). In order to validate the results of our RPPA anal-
ysis, we explored the levels of phosphorylated GSK3b
(Ser9) and Src (Tyr 416) proteins in parental MCF-10A and
DKI cells in the presence and absence of aspirin by Wes-
tern blot analysis. As shown in Fig. 4, GSK3b was sig-
nificantly more phosphorylated in aspirin-treated DKI cells
(Ex 9_KRAS) relative to aspirin-free control cells. How-
ever, the phosphorylation of GSK3b in parental MCF-10A
cells was unaltered by aspirin treatment. Densitometry on
three independent blots was performed for each cell line
with or without treatment. The intensity of phosphorylated
GSK3b was normalized to TUBB for each sample. The
ratio of aspirin-treated to untreated cells was 1.03 ± 0.066
for the parental MCF-10A cell line, while the ratio for DKI
cells was 1.37 ± 0.074. Student’s t test revealed a statis-
tically significant increase in phosphorylated GSK3b in
DKI cells, but not parental MCF-10A cells (P\ 0.01 and
P\ 0.5, respectively). Interestingly, quantification of
Western blots of single mutant KRAS and single mutant
PIK3CA cell lines revealed that phosphorylation of GSK3b
in each of these clones were unaltered by aspirin treatment
(1.1 ± 0.12, P = 0.2 and 0.96 ± 0.17, P = 0.9,
respectively) (n = 4). Similarly, aspirin treatment of DKI
(Ex 20_KRAS) cells did not result in a statistically sig-
nificant change in GSK3b phosphorylation (0.93 ± 0.16,
P = 0.7), indicating that aspirin’s effect on GSK3b is
specific to cells carrying mutations in the helical domain of
PIK3CA. Although RPPA analysis revealed an increase in
phosphorylated Src (Tyr 416) following aspirin treatment,
our Western blot analysis failed to validate this result (data
not shown).
PIK3CA mutations sensitize breast cancer cells
to aspirin treatment
In order to confirm that these findings were not limited to
our non-tumorigenic cellular system, we looked to validate
these findings in cancer cell lines. We obtained three
commercially-available breast cancer cell lines that dif-
fered in the mutational status of PIK3CA. The MCF-7 cell
line carries a mutation in PIK3CA (E545K), while MDA-
MB-468 and MDA-MB-436 are both homozygous for
wild-type PIK3CA and KRAS [25–27]. Treatment with
physiologic concentrations of aspirin resulted in a statisti-
cally significant decrease in cellular proliferation in MCF-
7, but not MDA-MB-468 or MDA-MB-436 cells, once
again indicating the need for mutations in PIK3CA (Fig. 5).
Western blot analysis revealed that aspirin treatment of
MCF-7 cells, but not MDA-MB-436 or MDA-MB-468,
resulted in a statistically significant increase in GSK3b
phosphorylation (Fig. 6).
Discussion
In this study, we set out to determine if mutations in
PIK3CA sensitized breast cancer cells to physiologic doses
of aspirin, as determined by the range of basal serum
aspirin levels previously described [28, 29]. We initially
observed only a modest effect of aspirin on cells carrying
mutant PIK3CA alone. However, we and others have
previously demonstrated that an accumulation of genetic
insults are necessary to observe changes more consistent
with a transformed phenotype [18, 30]. Consistent with
this, we observed a more dramatic reduction in the growth
of DKI cells, which carry mutations in KRAS, plus a
mutation in PIK3CA in either exon 9 or exon 20, relative to
clones carrying mutant PIK3CA alone following treatment
with aspirin (Fig. 1). In the current study, we used aspirin
concentrations as high as 4 mM. However, it is important
to note that lower daily aspirin doses may exhibit a more
modest effect on proliferation and apoptosis. Nonetheless,
others have reported that it is possible to safely reach serum
levels of aspirin as high as 10 mM, indicating that our
Fig. 4 Aspirin treatment results in increased phosphorylation of
GSK3b in a mutant PIK3CA-dependent manner. Western blot
analysis was performed on parental MCF-10A and DKI (Ex 9_KRAS)
clones following aspirin treatment against phosphorylated GSK3b
(Ser 9) and total GSK3b. TUBB was used as a loading control.
Western blot analysis revealed a statistically significant increase
(P\ 0.05) in the levels of phosphorylated GSK3b following 4 mM
aspirin treatment in DKI cells in comparison to non-treated controls
and parental MCF-10A cells, regardless of treatment. Blot is
representative of three independent experiments
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findings are clinically significant, as they are likely safe
and feasible [31].
PIK3CA is the most frequently mutated oncogene in
breast cancer. While KRAS is infrequently mutated in
breast cancers, KRAS can signal through PIK3CA, it is
plausible that aberrant PIK3CA activation could occur
through mutations in KRAS that could sensitize cells to
aspirin. However, the study by Liao et al. failed to find an
association between aspirin response and mutations in
KRAS, as only mutations in PIK3CA were associated with
a better response to aspirin [11]. Although KRAS is
mutated in 42 % of colorectal cancers, only 14 % of
samples also carry a mutation in PIK3CA [32, 33]. Thus, it
is possible that the sample size was insufficient to capture
an association with mutations in both PIK3CA and KRAS.
Another explanation may be that the requirement of mutant
Fig. 5 Aspirin effect on growth
of MCF-7, MDA-MB-468, and
MDA-MB-436 cancer cell lines.
Cell lines were seeded on day 0.
Following 24 h, aspirin (4 mM;
black) or no aspirin (white) was
added to the assay media.
Following 72 h, cells were
counted. Cell values for 4 mM
aspirin, for each cell line, were
normalized to the 0 mM aspirin
value for that particular cell
line. Cell death due to addition
of aspirin was observed in the
MCF-7 cell line. MDA-MB-468
and MDA-MB-436 cells did not
respond to aspirin treatment.
Values represent mean ± SD
(*P\ 0.05, n = 6)
Fig. 6 Breast cancer cells expression of GSK3b via Western blot.
MCF-7, MDA-MB-468, and MDA-MB-436 cells were seeded on day
0. Next day, the media were replaced, and cells were treated with
4 mM aspirin or no aspirin. After 48 h, media and aspirin were
replenished. The next day, cells were harvested in Laemmli buffer,
and Western blot was performed to probe for phosphorylated GSK3b
(Ser 9) and total GSK3b. ACTB was used as a loading control.
Western blot analysis demonstrated that levels of phosphorylated
GSK3b following aspirin (4 mM) treatment in MCF-7 cells were
slightly increased in comparison to non-treated samples. Figure is
representative of three independent experiments
Breast Cancer Res Treat (2016) 156:33–43 39
123
KRAS toward aspirin sensitivity can be substituted with
genetic alterations in other genes. Therefore, when KRAS
is wild type, genetic alterations in other genes can suffice.
Molecular pathologic epidemiology (MPE) [34, 35]
performed by the Liao et al. study reported a strong asso-
ciation in aspirin response in patients whose cancers car-
ried mutations in PIK3CA. Similarly, we report that
mutations in PIK3CA are required for aspirin sensitivity.
This requirement was further validated by the breast cancer
cell lines in our study, as only MCF-7 cells, which carry a
mutation in PIK3CA responded to aspirin treatment. MCF-
7 cells carry wild-type KRAS but do carry several other
genetic alterations, one or more of which provide the
oncogenic stimulus necessary to replace mutant KRAS.
Taken together, we concluded that multiple oncogenic
insults were required to observe the growth inhibitory
effects of aspirin, but a mutation in PIK3CA is necessary,
as cellular clones carrying mutant KRAS alone were not
responsive to aspirin treatment.
Previous retrospective analyses investigating aspirin use
in colorectal cancers in the context of mutant PIK3CA
status did not report where PIK3CA was mutated [11, 12].
Thus, the potential differences in phenotype across
PIK3CA mutations were not evaluated in these studies.
Mutations in PIK3CA occur primarily in two hotspot
regions located in either the helical (exon 9) or the kinase
(exon 20) domains. In our studies, clones carrying a single
mutation at exon 20 were less sensitive to aspirin than exon
9 mutants. Similarly, exon 9 DKI cells were more sensitive
to aspirin then exon 20 DKI cells, with DKI cells exhibiting
increased sensitivity relative to their respective single
PIK3CA mutant clones. These mutations are reported to
have similar consequences, but fundamental differences
have been reported [36, 37]. The difference in aspirin
sensitivity between mutant exon 9 or exon 20 clones may
be attributed to differences in the aberrant activation of
signaling pathways. A recent study by Blair et al. demon-
strated differential phosphorylation patterns between cell
lines harboring mutations in either exon 9 or exon 20 [37].
The authors reported that growth signaling in cells carrying
mutations in exon 20 was largely dependent on ERBB3
phosphorylation for complete pathway activation, while
cellular clones with mutations in exon 9 were not as
affected by ERBB3 phosphorylation. However, a mutation
in exon 9 resulted in the increased phosphorylation of a
number of peptides not found to be activated in mutant
exon 20 clones.
A large body of literature has reported exploring the
cytotoxicity of aspirin in breast cancer cells [38–40].
However, several mechanisms have been implicated. Using
MCF-7 breast cancer cells, Choi et al. [38] reported that
aspirin-induced apoptosis was the result of changes in Bcl-
2 protein expression [38]. A separate study using neuro-2a
cells showed that aspirin-induced apoptosis was caused by
a decrease in proteasome activity [39], while Yan et al. [40]
observed that aspirin-induced apoptosis in MDA-MB-453
breast cancer cells was triggered by an increase in caspase-
3 expression [40]. Thus, several different mechanisms of
action have been proposed. Moreover, to date, no study has
explored clinical outcomes in breast cancer in the context
of any specific mutational backgrounds. In our study,
RPPA analysis revealed that aspirin treatment resulted in
significantly increased phosphorylation of GSK3b in DKI
cells, but not parental MCF-10A cells relative to aspirin-
free controls. GSK3b has been implicated in cellular
growth signaling and is a downstream target of the PI3K-
AKT pathway [41, 42]. However, the role of GSK3b in
cancer has been controversial, as phosphorylation has been
reported as inhibitory and activating [17, 43, 44]. Further
support for the latter comes from Wang et al. [43], which
demonstrated that GSK3b has been shown to support the
growth of MLL leukemia cells [43]. We have previously
reported that mutations in PIK3CA resulted in hyperphos-
phorylation of GSK3b, which sensitized cells to pharma-
cologic inhibition of GSK3b [17, 45]. Indeed, in the current
study, we did observe an increase in basal levels of phos-
phorylated GSK3b in DKI cells, which was further aug-
mented following aspirin treatment, as indicated by
Western blot analysis. Moreover, this increase in phos-
phorylated GSK3b led to increased cytotoxicity, as repor-
ted by flow cytometry and a concomitant decrease in cell
number.
The role of GSK3b in the response to aspirin remains
elusive. One explanation may be increased stability of
phosphorylated GSK3b. Others have reported that col-
orectal cancer cells treated with aspirin experienced
increased phosphorylation of GSK3b and b-catenin but did
not explore the association with the mutational status of
PIK3CA [46]. This same group suggests that aspirin
treatment may stabilize serine/threonine phosphorylations
through the inhibition of a specific phosphatase but were
unable to determine which phosphatase was being inhib-
ited. Later work by Bos et al. reported that aspirin treat-
ment resulted in increased phosphorylation of the
phosphatase PP2A, which results in its inactivation [47].
PP2A has been shown to dephosphorylate both GSK3b and
b-catenin and inactivation of PP2A could result in
stable phosphorylation of both proteins. Mutations in
PIK3CA result in aberrant phosphorylation of AKT,
mTOR, and GSK3b [17]. Thus, mutations in PIK3CA
coupled with inactivation of PP2A by aspirin may lead to
even more durable phosphorylation of GSK3b. Others have
reported that phosphorylation of GSK3b results in growth
inhibition of cells [48]. Therefore, elevated GSK3b phos-
phorylation from aberrant PIK3CA signaling coupled with
inhibition of the PP2A phosphatase may be leading to a
40 Breast Cancer Res Treat (2016) 156:33–43
123
long-lasting inhibitory phosphorylation signal on GSK3b,
which may be the cause of aspirin sensitivity in mutant
PIK3CA-containing cells.
In addition to aspirin’s anti-proliferative properties,
other effects on tumor progression have been reported.
Maity et al. shows that pretreatment of MCF-7 and MDA-
MB-231 cells with aspirin caused a decrease in cell
migration, which was irreversible [49]. The study by Lloyd
et al. reported that aspirin suppresses cell adhesion and cell
motility in the prostate cancer cell line PC-3 [50]. Lastly,
aspirin treatment decreased the invasiveness of the human
cervical cancer cell line Hela [51]. Although these prop-
erties are hallmarks of cancer, none of these studies show
an association with mutant PIK3CA status, as all of these
cell lines only carry wild-type PIK3CA, with the exception
of MCF-7. However, in the study by Maity et al., both
mutant PIK3CA-containing and wild-type PIK3CA-con-
taining cells exhibited the same phenotype. Therefore, it is
unlikely that mutant PIK3CA is a factor in these other
aspirin-induced properties.
MDA-MB-468 cells carry wild-type PIK3CA and did
not respond to aspirin. Of note, these cells harbor a
mutation in the tumor suppressor gene PTEN. Some studies
have suggested that loss of PTEN is equivalent to harboring
a mutation in PIK3CA; however, we and others have shown
that genetic insults to these two genes result in different
phenotypes [45]. PTEN loss has been shown to result in
aberrant AKT phosphorylation [52]. Thus, since both
MDA-MB-468 and MDA-MB-436 cells do not express
functional PTEN and are insensitive to aspirin, this implies
that the sensitivity to aspirin is an AKT-independent
mechanism. Our study suggests that cancer cells carrying
mutations in PTEN, but not PIK3CA, will not respond to
aspirin.
The current study highlights how isogenic, genetically
clean, non-tumorigenic cell lines can be used as a powerful
tool for elucidating drug response. Herein, we provide the
first evidence that mutations in PIK3CA sensitize breast
cancer cells to aspirin therapy. Furthermore, our results
implicate hyperphosphorylation of GSK3b as a possible
mechanism and a biomarker that could predict the best
responders to aspirin therapy. Taken together with the
results of previous retrospective analyses of colorectal
cancer specimens, these findings highlight the possibility
that aspirin could be used as an adjuvant therapy or a
preventive agent. Our next step will be to validate these
findings in a retrospective study evaluating breast cancer
specimens from patients carrying mutations in PIK3CA
who used daily aspirin therapy.
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